Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences, Inc. (PLSE) is a pioneering clinical-stage electroceutical company focused on the commercial application of its proprietary Nano-Pulse Stimulation (NPS) technology. Headquartered in Hayward, CA, the company's core mission is to leverage this novel technology to improve and extend patient lives, addressing the distinct needs of patients and physicians alike.
Nano-Pulse Stimulation Technology
NPS is a cutting-edge, non-thermal, drug-free energy-based technology that utilizes ultra-short nanosecond electrical pulses to impact cell membranes and intracellular structures. This method promotes unique cellular behaviors and can induce specific immune responses, opening up a myriad of therapeutic possibilities. Unlike conventional treatments, NPS delivers electrical pulses in billionths of a second, providing targeted effects without damaging surrounding tissues.
Applications and Innovations
Pulse Biosciences is actively exploring the potential of its NPS technology across various medical fields. Key areas of investigation include immuno-oncology, where NPS may be used to treat cancer by modulating the immune system's response, and dermatology, for treatments that require precise, non-invasive interventions. The technology's unique biologic effects position it as a promising solution for conditions lacking optimal treatments.
Recent Achievements and Projects
The company has made significant strides in both preclinical and clinical studies, demonstrating the safety and efficacy of NPS technology. Recent projects have focused on refining device capabilities, enhancing treatment protocols, and expanding the scope of applications. Partnerships with leading medical institutions and ongoing collaborations with researchers underscore Pulse Biosciences' commitment to innovation.
Financial Condition
Pulse Biosciences generates substantial revenue primarily from the sale of its systems in North America. The company continues to invest in research and development to further advance its technology and explore new market opportunities.
For those looking to stay updated on the latest developments, performance, and news related to Pulse Biosciences, Inc., StockTitan provides a comprehensive and timely resource.
Pulse Biosciences, Inc. (Nasdaq: PLSE) reported no revenue in Q4 2022 due to the discontinuation of commercial dermatology activities. For the full year, revenue reached $700,000, primarily from earlier in the year. Q4 GAAP expenses decreased to $8.7 million from $16.3 million YoY, while the net loss shrank to $9.2 million from $15.4 million. Total cash reserves increased to $61.1 million as of December 31, 2022, up from $28.6 million in 2021. The company is focused on developing NS PFA delivery devices for atrial fibrillation treatments, with a pre-submission meeting with the FDA planned for 2Q23.
Pulse Biosciences, Inc. (PLSE) announced it will release its financial results for Q4 and the full year of 2022 on March 30, 2023, after market close. A conference call will follow at 1:30 PM PT / 4:30 PM ET. The company is focused on its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation, aiming to enhance patient outcomes. Investors can join the call by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally. More details are available on their website.
Pulse Biosciences (NASDAQ: PLSE) announced its nsPFA™ System showcased in a poster presentation at the 28th Annual International AF Symposium in Boston from February 2-4. The technology integrates with CardioNXT’s iMap system, demonstrating effective cardiac ablation and mapping capabilities. The preclinical studies suggest that the nsPFA System may improve patient outcomes by combining advanced technologies for treating atrial fibrillation. CEO Kevin Danahy indicated optimism about early results, emphasizing the potential of the new catheter system.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
What is Pulse Biosciences, Inc.?
What is Nano-Pulse Stimulation (NPS) technology?
What are the primary applications of NPS technology?
Where is Pulse Biosciences, Inc. headquartered?
How does NPS technology differ from traditional treatments?
What recent achievements has Pulse Biosciences made?
What are the financial sources for Pulse Biosciences?
How does Pulse Biosciences contribute to medical innovation?
What is the mission of Pulse Biosciences?
How can I get the latest updates on Pulse Biosciences?
